Aerovate Therapeutics Stock (NASDAQ: AVTE) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 146.721K |
Day Range | - - - |
52 Wk Range | 9.410 - 32.415 |
Market Cap | $569.862M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 38 |
Short Interest | 11.17% |
Days to Cover | 7.4 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Aerovate Therapeutics (NASDAQ: AVTE) through any online brokerage.
Other companies in Aerovate Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV), Valneva (NASDAQ:VALN) and Celcuity (NASDAQ:CELC).
The latest price target for Aerovate Therapeutics (NASDAQ: AVTE) was reported by Wells Fargo on Monday, April 1, 2024. The analyst firm set a price target for 35.00 expecting AVTE to rise to within 12 months (a possible 76.50% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Aerovate Therapeutics (NASDAQ: AVTE) is $19.83 last updated May 10, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Aerovate Therapeutics.
Aerovate Therapeutics’s Q2 earnings are confirmed for Monday, August 12, 2024.
There is no upcoming split for Aerovate Therapeutics.
Aerovate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.